Treace Medical Concepts, Inc. revised revenue guidance for the year 2023. The company is updating its full-year 2023 revenue guidance to $182 million to $186 million, which represents approximately 28% to 31% growth over the Company?s 2022 revenue. This compares to the prior full-year 2023 revenue guidance of $191 million to $197 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.385 USD | -4.35% | +22.26% | -58.00% |
12:25pm | North American Morning Briefing : The "Everything -2- | DJ |
May. 16 | UBS Downgrades Treace Medical Concepts to Neutral From Buy, Cuts Price Target to $6.50 From $16 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.00% | 349M | |
+73.42% | 12.42B | |
-19.64% | 7.81B | |
+3.46% | 6.4B | |
+13.65% | 5.45B | |
+38.48% | 5.01B | |
-17.43% | 4.84B | |
-19.78% | 4.19B | |
-28.90% | 2.69B | |
+46.35% | 2.39B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Revises Revenue Guidance for the Year 2023